Table 3.
IPTW-weighted model estimated expenditures of 1-year costs after confirmed diagnosis and related cost differences with 95% confidence intervals
| Non-specialised centre | Specialised ILD centre | Difference (in €) | |
|---|---|---|---|
| Costs in € (95% CI) | Costs in € (95% CI) | ||
| Overall | |||
| Totala | 13,953 (13,554; 14,353) | 13,082 (12,252; 13,906) | − 872 (− 75; 1817) |
| Inpatientb | 8814 (8482; 9164) | 6970 (6364; 7606) | − 1845 (− 2609; − 1133)* |
| Outpatienta | 1378 (1349; 1406) | 1363 (1266; 1453) | − 15 (− 117; 76) |
| Pharmaceuticalsa | 3761 (3590; 3927) | 4753 (4287; 5243) | 992 (488; 1562)* |
| Respiratory-related | |||
| Totalb | 3717 (3546; 3897) | 4385 (3966; 4855) | 669 (219; 1156)* |
| Inpatientb | 2206 (2076; 2352) | 1762 (1543; 1993) | − 444 (− 709; − 175)* |
| Outpatientb | 482 (467; 496) | 498 (452; 552) | 17 (− 32; 70) |
| Pharmaceuticalsb | 1029 (936; 1130) | 2121 (1754; 2497) | 1092 (759; 1464)* |
Estimation based on weighted one- and two-part generalized linear gamma models via recycled predictions approach with 1000 bootstrap replicates
CI: Confidence interval, ILD: Interstitial lung disease, IPTW: Inverse probability of treatment weighting
*Statistically significant results
aOne-part model
bTwo-part model